Home > Insider Trading > Filing (0001567619-20-011545)

Filing Details

Accession Number:: 0001567619-20-011545
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-06-02 17:01:44
Reporting Period:: 2020-05-29

Accepted Time:: 2020-06-02 17:01:44
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
874716	Idexx Laboratories Inc	IDXX	In Vitro & In Vivo Diagnostic Substances (2835)	010393723

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1500399	Giovani Twigge	Idexx Laboratories, Inc. One Idexx Drive Westbrook ME 04092	Corporate Vice President	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-05-29	12,814	$62.00	25,706	No	4	M	Direct
Common Stock	Acquisiton	2020-05-29	1,256	$79.54	26,962	No	4	M	Direct
Common Stock	Disposition	2020-05-29	359	$304.76	26,603	No	4	S	Direct
Common Stock	Disposition	2020-05-29	1,600	$306.21	25,003	No	4	S	Direct
Common Stock	Disposition	2020-05-29	3,948	$306.99	21,005	No	4	S	Direct
Common Stock	Disposition	2020-05-29	3,296	$307.99	17,759	No	4	S	Direct
Common Stock	Disposition	2020-05-29	4,867	$308.88	12,892	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Option (right-to-buy)	Disposition	2020-05-29	12,814	$0.00	12,814	$62.00
Common Stock	Incentive Stock Option (right-to-buy)	Disposition	2020-05-29	1,256	$0.00	1,256	$79.54

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2024-02-13	No	4	M	Direct
0		2025-02-13	No	4	M	Direct

Footnotes

Includes 23 shares purchased under the Issuer's Employee Stock Purchase Plan on March 31, 2020.
Represents the weighted average price of the shares sold ranging from a low of $304.46 to a high of $304.98 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Represents the weighted average price of the shares sold ranging from a low of $305.55 to a high of $306.47 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Represents the weighted average price of the shares sold ranging from a low of $306.58 to a high of $307.55 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Represents the weighted average price of the shares sold ranging from a low of $307.60 to a high of $308.41 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Represents the weighted average price of the shares sold ranging from a low of $308.62 to a high of $309.40 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Grant of option to buy 6,407 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five annual installments beginning February 14, 2015 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
Grant of option to buy 628 shares of IDEXX Laboratories, Inc. common stock that became exercisable on February 14, 2020 without giving effect to Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
Not applicable.